Načítá se...
Prolonged use of pegylated liposomal doxorubicin in gynecologic malignancies
Pegylated liposomal doxorubicin (PLD) is a palliative treatment option for patients with recurrent gynecologic malignancies. It has an appealing toxicity profile and responses can be prolonged. There is no consensus as to the level of cardiac toxicity. Current label warnings, National Comprehensive...
Uloženo v:
| Vydáno v: | Gynecol Oncol Rep |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Elsevier
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6710555/ https://ncbi.nlm.nih.gov/pubmed/31467958 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.gore.2019.07.012 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|